
Yashpal Singh Malik
Deputy Director General (Agricultural Education)Indian Council of Agricultural Research, Headquarters, New Delhi , India

Submitted
2024/12/16First Online
2025/04/30doi
10.18805/IJAR.B-5540Cite article - Jayashree Sarma, Nagendra Nath Barman, Sophia M. Gogoi, Lukumoni Buragohain, Durlav Prasad Bora, Arpita Bharali, Arijit Shome, Sutopa Das. (2025). Neutralisation Efficacy of Classical Swine Fever C-strain Specific Vaccine Antibody against Genotype 2. Indian Journal of Animal Research. 60(7): 1243–1250. doi: 10.18805/IJAR.B-5540
Background: Classical swine fever, a highly endemic pig disease in India, particularly in the NER, spots Assam with the highest outbreaks. Despite available CSF vaccines, concern prevails over protective immune response of C-strain vaccine, as emerging genotype 2 replaces genotype 1 globally, causing outbreak in immunized herds.
Methods: The study assessed the cross-protective and cross-neutralization potency of existing vaccines against additional prevalent genotypes. Archived CSFV samples were reconfirmed by S-ELISA and nRT-PCR. Following E2 full-length genome sequencing and phylogeny (MEGA-X), representative CSFV samples from NER were isolated in PK-15 cell line. Hyper-immune serum was raised to test neutralization and cross–neutralization efficacy.
Result: Of 77 archived samples, 43 were S-ELISA positive and 47 nRT-PCR. Phylogenetic analysis revealed either 1.1 or 2.2 sub-genotypes. Virus titre was 4.49-5.16 log TCID 50 per ml in four samples representing two sub-genotypes (1.1 and 2.2) after 5 passages in PK-15 cells. Neutralization assay showed complete neutralization for sub-genotype 1.1, sub-genotype 2.2 showed 84% with C-strain specific antibody. The study revealed prevalence of both sub-genotypes 1.1 and 2.2 in NER with lower neutralization efficacy of vaccine strain antibodies to heterologous genotypes with conserved immunogenic epitope.
Distinguished scholars and subject experts committed to editorial excellence, scientific integrity and rigorous peer review.
View Full Board